Growth Metrics

Rigel Pharmaceuticals (RIGL) Gross Profit (2018 - 2025)

Rigel Pharmaceuticals (RIGL) has 8 years of Gross Profit data on record, last reported at $63.8 million in Q4 2025.

  • For Q4 2025, Gross Profit rose 23.24% year-over-year to $63.8 million; the TTM value through Dec 2025 reached $274.7 million, up 70.99%, while the annual FY2025 figure was $274.7 million, 70.99% up from the prior year.
  • Gross Profit reached $63.8 million in Q4 2025 per RIGL's latest filing, down from $64.7 million in the prior quarter.
  • Across five years, Gross Profit topped out at $97.2 million in Q2 2025 and bottomed at $16.6 million in Q1 2022.
  • Average Gross Profit over 5 years is $40.6 million, with a median of $30.4 million recorded in 2022.
  • Peak YoY movement for Gross Profit: tumbled 79.41% in 2022, then skyrocketed 185.54% in 2025.
  • A 5-year view of Gross Profit shows it stood at $19.9 million in 2021, then skyrocketed by 155.68% to $50.9 million in 2022, then plummeted by 37.17% to $32.0 million in 2023, then soared by 61.89% to $51.8 million in 2024, then increased by 23.24% to $63.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $63.8 million in Q4 2025, $64.7 million in Q3 2025, and $97.2 million in Q2 2025.